ホーム>>Signaling Pathways>> Immunology/Inflammation>> NO Synthase>>Dehydroevodiamine

Dehydroevodiamine

カタログ番号GC38431

デヒドロエボジアミンは、Evodiae Fructus から分離された主要な生理活性キナゾリン アルカロイドであり、モルモットの心室筋細胞で抗不整脈効果があります 。

Products are for research use only. Not for human use. We do not sell to patients.

Dehydroevodiamine 化学構造

Cas No.: 67909-49-3

サイズ 価格 在庫数 個数
1mg
$36.00
在庫あり
5mg
$52.00
在庫あり
10mg
$81.00
在庫あり
20mg
$143.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes[1]. Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells[2].

Dehydroevodiamine (0-50 μM; 2 hours) inhibits iNOS and COX-2 expression and prevents degradation of IκB-α in LPS induced RAW 264.7 macrophages[2]. Dehydroevodiamine (0-50 μM; 2 hours) inhibits a LPS-induced increase in the iNOS and COX-2 mRNA expression[2]. Western Blot Analysis[2] Cell Line: RAW 264.7 macrophage cells

[1]. Loh SH, et al. Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes. J Ethnopharmacol. 2014 May 14;153(3):753-62. [2]. Noh EJ, et al. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. 2006 Jul 10;79(7):695-701. Epub 2006 Mar 6.

レビュー

Review for Dehydroevodiamine

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dehydroevodiamine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.